MAPK kinase 3 Is a tumor suppressor with reduced copy number in breast cancer

Cancer Research

Volumn 74, Issue 1, 2014, Pages 162-172

  MacNeil, Adam J ^a,c   Jiao, Shun Chang ^d   McEachern, Lori A ^a   Yang, Yong Jun ^e   Dennis, Amanda ^a   Yu, Haiming ^d   Xu, Zhaolin ^b,c   Marshall, Jean S ^a,c   Lin, Tong Jun ^a,b,c  

^a Department of Microbiology and Immunology ^*  (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

^c Beatrice Hunter Cancer Research Institute   (Canada)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE ACTIVITY; GENE DOSAGE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; MKK3 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE DOSAGE; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MAP KINASE KINASE 3; MICE; MICE, TRANSGENIC; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 84892724354     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1310     Document Type: Article

References (51)

1. Harris H, Miller OJ, Klein G, Worst P, Tachibana T. Suppression of malignancy by cell fusion. Nature 1969;223:363-8.
2. Sherr CJ. Principles of tumor suppression. Cell 2004;116:235-46.
3. Han J, Sun P. The pathways to tumor suppression via route p38. Trends Biochem Sci 2007;32:364-71.
4. Schramek D, Kotsinas A, Meixner A, Wada T, Elling U, Pospisilik JA, et al. The stress kinaseMKK7couples oncogenic stress to p53 stability and tumor suppression. Nat Genet 2011;43:212-9.
5. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41.
6. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009;458:719-24.
7. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 2011;476:163-9.
8. Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Ursule L, et al. Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes. Cancer Res 2004;64:6453-60.
9. Lin K, Lane B, Carter A, Johnson GG, Onwuazor O, Oates M, et al. The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p. Br J Haematol 2012; 160:53-62.
10. Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E, et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 2006;16:1465-79.
11. Jia M, Souchelnytskyi N, Hellman U, O'Hare M, Jat PS, Souchelnytskyi S. Proteome profiling of immortalization-to-senescence transition of human breast epithelial cells identified MAP2K3 as a senescencepromoting protein which is downregulated in human breast cancer. Proteomics. Clinical Applications 2010;4:816-28.
12. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
13. Teng DH, Chen Y, Lian L, Ha PC, Tavtigian SV, Wong AK. Mutation analyses of 268 candidate genes in human tumor cell lines. Genomics 2001;74:352-64.
14. Li B, Power MR, Lin TJ. De novo synthesis of early growth response factor-1 is required for the full responsiveness of mast cells to produce TNF and IL-13 by IgE and antigen stimulation. Blood 2006;107: 2814-20.
15. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 2002;99:12963-8.
16. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global variation in copy number in the human genome. Nature 2006; 444:444-54.
17. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogenactivated protein kinase signal transduction pathway. Mol Cell Biol 1996;16:1247-55.
18. Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. The stressactivated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem 2002;277:29792-802.
19. Waas WF, Lo HH, Dalby KN. The kinetic mechanism of the dual phosphorylation of the ATF2 transcription factor by p38 mitogenactivated protein (MAP) kinase alpha. Implications for signal/response profiles of MAP kinase pathways. J Biol Chem 2001;276: 5676-84.
20. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995;9: 935-44.
21. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
22. Jung YS, Qian Y, Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal 2010; 22:1003-12.
23. Wong KB, DeDecker BS, Freund SM, Proctor MR, Bycroft M, Fersht AR. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci U S A 1999;96:8438-42.
24. Kardassis D, Papakosta P, Pardali K, Moustakas A. c-Jun transactivates the promoter of the human p21(WAF1/Cip1) gene by acting as a superactivator of the ubiquitous transcription factor Sp1. J Biol Chem 1999;274:29572-81.
25. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131-49.
26. Borriello A, Bencivenga D, Criscuolo M, Caldarelli I, Cucciolla V, Tramontano A, et al. Targeting p27Kip1 protein: its relevance in the therapy of human cancer. Expert Opinion on Therapeutic Targets 2011;15:677-93.
27. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nature Reviews. Cancer 2009;9:400-14.
28. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Reviews in Molecular Medicine 2008;10:e19.
29. Pellikainen MJ, Pekola TT, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, et al. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol 2003;56:214-20002E
30. Alkarain A, Jordan R, Slingerland J. p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia 2004;9:67-80.
31. 1 arrest via mutually compensatory activation of MKK3 and MKK6. Int J Oncol 2011;38:419-26.
32. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 2004;36:343-50.
33. Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E, et al. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 2007;26:2502-6.
34. Stivala LA, Cazzalini O, Prosperi E. The cyclin-dependent kinase inhibitor p21CDKN1A as a target of anti-cancer drugs. Current Cancer Drug Targets 2012;12:85-96.
35. Azuma Y, Watanabe K, Date M, Daito M, Ohura K. Possible involvement of p38 in mechanisms underlying acceleration of proliferation by 15-deoxy-Delta(12,14)-prostaglandin J2 and the precursors in leukemia cell line THP-1. J Pharmacol Sci 2004;94:261-70.
36. Permpongkosol S, Wang JD, Takahara S, Matsumiya K, Nonomura N, Nishimura K, et al. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling FAK, cell-cycle entry and apoptosis. Int J Cancer 2002;98:167-72.
37. Cabane C, Englaro W, Yeow K, Ragno M, Derijard B. Regulation of C2C12 myogenic terminal differentiation by MKK3/p38alpha pathway. Am J Physiol Cell Physiol 2003;284:C658-66.
38. Faust D, Dolado I, Cuadrado A, Oesch F, Weiss C, Nebreda AR, et al. p38alpha MAPK is required for contact inhibition. Oncogene 2005; 24:7941-5.
39. Cazillis M, Bringuier AF, Delautier D, Buisine M, Bernuau D, Gespach C, et al. Disruption of MKK4 signaling reveals its tumor-suppressor role in embryonic stem cells. Oncogene 2004;23:4735-44.
40. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377:552-7.
41. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
42. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. Embo J 1999;18:6845-54.
43. She QB, Chen N, Dong Z. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J Biol Chem 2000; 275:20444-9.
44. Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem 2002;277:47976-9.
45. Yagi A, Hasegawa Y, Xiao H, Haneda M, Kojima E, Nishikimi A, et al. GADD34 induces p53 phosphorylation and p21/WAF1 transcription. J Cell Biochem 2003;90:1242-9.
46. Zeng PY, Berger SL. LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. Cancer Res 2006;66: 10701-8.
47. Izutani Y, Yogosawa S, Sowa Y, Sakai T. Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells. Int J Oncol 2012;40:816-24.
48. Han Q, Leng J, Bian D, Mahanivong C, Carpenter KA, Pan ZK, et al. Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells. J Biol Chem 2002;277:48379-85.
49. Al-Haj L, Blackshear PJ, Khabar KS. Regulation of p21/CIP1/WAF-1 mediated cell-cycle arrest by RNase L and tristetraprolin, and involvement of AU-rich elements. Nucleic Acids Res 2012;40: 7739-52.
50. Scoumanne A, Cho SJ, Zhang J, Chen X. The cyclin-dependent kinase inhibitor p21 is regulated by RNA-binding protein PCBP4 via mRNA stability. Nucleic Acids Res 2010;39:213-24.
51. Ziegeler G, Ming J, Koseki JC, Sevinc S, Chen T, Ergun S, et al. Embryonic lethal abnormal vision-like HuR-dependent mRNA stability regulates post-transcriptional expression of cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem 2010;285:15408-19.